Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine Inc (EDIT) today and set a price target of $55. The company’s shares opened today at $26.34.
Livshits commented:
“We understand Caribou Biosciences (private) is also developing CRISPR edited programs based on iPSCs.”
According to TipRanks.com, Livshits is a 2-star analyst with an average return of 1.5% and a 50.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
Currently, the analyst consensus on Editas Medicine Inc is a Strong Buy with an average price target of $42.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.43 and a one-year low of $17.80. Currently, Editas Medicine Inc has an average volume of 1.01M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EDIT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
